首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1649519

全球抗纖溶藥物市場預測（2025-2030）

Global Anti-Fibrinolytic Drug Market - Forecasts from 2025 to 2030

出版日期: 2025年01月30日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

抗纖溶藥物市場預計將從 2025 年的 373.54 億美元成長到 2030 年的 518.27 億美元，複合年成長率為 6.77%。

抗纖維蛋白溶解藥物旨在減緩血栓溶解，對於治療月經過多和其他類型的出血至關重要。這些藥物在防止鼻腔、口腔和女性生殖道等易發生纖維蛋白溶解的部位血栓破裂方面發揮重要作用。大多數手術都是在醫院和診所進行，因此對抗纖溶藥物的需求尤其強烈。由於出血性疾病的增加、創傷和手術事故的增加、技術進步以及老年人口的成長等多種因素，全球抗纖溶藥物市場預計將擴大。這些因素導致對抗纖溶藥物的需求增加，以控制出血事件、控制創傷期間的失血以及提高治療的有效性和安全性。老化社會特別容易受到出血性疾病及其併發症的影響，這進一步增加了對抗纖溶藥物的需求。

全球抗纖溶藥物市場的關鍵促進因素

1. 外科手術中的外科手術：全球外科手術數量的增加是市場成長的主要驅動力。抗纖溶藥物在各種外科手術中至關重要，包括心血管和牙科手術，因為它們可以減少出血。

2. 道路交通事故增加：世界衛生組織（WHO）估計，每年因道路交通事故死亡的人數約為135萬人。由於這些藥物具有防止溶栓和減少出血的作用，因此其需求受到道路交通事故發生率上升的影響很大。

3.月經失調管理：女性越來越多使用抗纖維蛋白溶解藥物來控制月經量，有助於市場擴張。

4. 技術進步：藥物配方和輸送機制的創新提高了治療效果和安全性。

地理見解

北美：由於大型製藥公司的存在和手術的高普及率，該地區預計將佔據抗纖溶藥物市場的大部分佔有率。
亞太地區 (APAC)：由於道路交通死亡率和受傷率高，預計亞太地區將顯著成長。該地區每年約有 645,000 人因道路交通事故喪生，對抗纖溶藥物的需求強勁。此外，女性對月經健康的認知不斷增強，進一步推動了市場的成長。

總而言之，由於手術需求、事故率上升、醫療技術的進步以及人口老化等人口因素，全球抗纖溶藥物市場將大幅成長。

為什麼要購買這份報告？

深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

2022 年至 2030 年的實際資料和預測
成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
競爭定位、策略與市場佔有率分析
各地區（包括細分市場和國家）的收益成長和預測分析
公司概況（策略、產品、財務、主要發展等）

介紹
北美洲
- 按適應症
- 依給藥途徑
- 按最終用戶
- 按國家
南美洲
- 按適應症
- 依給藥途徑
- 按最終用戶
- 按國家
歐洲
- 按適應症
- 依給藥途徑
- 按最終用戶
- 按國家
中東和非洲
- 按適應症
- 依給藥途徑
- 按最終用戶
- 按國家
亞太地區
- 按適應症
- 依給藥途徑
- 按最終用戶
- 按國家

第9章競爭格局及分析

主要企業和策略分析
市場佔有率分析
合併、收購、協議和合作
競爭儀錶板

第10章公司簡介

Pfizer Canada ULC
Zydus Pharmaceuticals, Inc.
Viatris Inc.
Xanodyne Pharmaceuticals, Inc.
American Regent, Inc.（Daiichi Sankyo Group）
Kedrion Biopharma
Bayer
Grifols
CSL Behring

簡介目錄

Product Code: KSI061613515

The global anti-fibrinolytic drug market is anticipated to grow at a CAGR of 6.77%, increasing from US$37.354 billion in 2025 to US$51.827 billion by 2030.

Antifibrinolytic drugs are designed to slow the dissolution of blood clots, making them essential for treating heavy menstrual bleeding and other types of hemorrhages. These agents play a critical role in preventing clot degradation in areas prone to fibrinolysis, such as the nasal cavity, oral cavity, and female reproductive tract. The demand for antifibrinolytic drugs is particularly strong in hospitals and clinics, where most surgeries occur. As the number of surgical procedures increases globally, the need for these medications to manage bleeding effectively is expected to drive market growth.The global antifibrinolytic drug market is anticipated to expand due to several factors, including a rise in bleeding disorders, an increase in trauma and surgical incidents, technological advancements, and a growing elderly population. These factors create a heightened demand for antifibrinolytic medications to manage bleeding episodes, control blood loss in trauma situations, and improve treatment efficacy and safety. The aging population is especially vulnerable to bleeding disorders and their complications, further increasing the need for these drugs.

Key Drivers of the Global Antifibrinolytic Drug Market:

1. Surge in Surgical Procedures: The increasing number of surgeries worldwide is a primary driver of market growth. Antifibrinolytic drugs are crucial during various surgical operations, including cardiovascular and dental procedures, as they help minimize bleeding.

2. Rise in Road Traffic Accidents: The World Health Organization (WHO) estimates that approximately 1.35 million fatalities occur annually due to road traffic accidents. Given that these drugs prevent clot lysis and mitigate blood loss, their demand is significantly influenced by the rising incidence of road injuries.

3. Management of Menorrhagia: The growing use of antifibrinolytic drugs among women to control heavy menstrual flow contributes to market expansion.

4. Technological Advancements: Innovations in drug formulations and delivery mechanisms enhance treatment effectiveness and safety.

Geographical Insights:

North America: This region is expected to hold a significant share of the antifibrinolytic drug market due to the presence of major pharmaceutical companies and a high prevalence of surgeries. The adoption of these drugs for managing menstrual flow also plays a key role in market growth.
Asia-Pacific (APAC): The APAC region is projected to experience substantial growth due to a high rate of road traffic injuries and accidents. With approximately 645,000 lives lost each year from road accidents in this region, there is a strong demand for antifibrinolytic medications. Additionally, increased health awareness among women regarding menstrual health further drives market growth.

In summary, the global antifibrinolytic drug market is poised for significant growth driven by surgical demands, rising accident rates, advancements in medical technology, and demographic factors such as an aging population.

Reasons for buying this report:-

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data & forecasts from 2022 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-fibrinolytic drug market is segmented and analyzed as below:

By Indication

Surgeries
Cardiac
Dental
Others
Menorrhagia
Hereditary Angioedema (HAE)

By Route of Administration

Oral
Injection

By End-User

Hospital and Clinics
Ambulatory Surgical Centers

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
UK
Spain
Italy
Others
Middle East and Africa
Saudi Arabia
Israel
UAE
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Taiwan
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings
3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY INDICATION

5.1. Introduction
5.2. Surgeries
- 5.2.1. Cardiac
- 5.2.2. Dental
- 5.2.3. Others
5.3. Menorrhagia
5.4. Hereditary Angioedema (HAE)

6. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY ROUTE OF ADMINISTRATION

6.1. Introduction
6.2. Oral
6.3. Injection

7. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY END-USER

7.1. Introduction
7.2. Hospital and Clinics
7.3. Ambulatory Surgical Centers

8. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Indication
- 8.2.2. By Route of Administration
- 8.2.3. By End-User
- 8.2.4. By Country
  - 8.2.4.1. USA
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Indication
- 8.3.2. By Route of Administration
- 8.3.3. By End-User
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Indication
- 8.4.2. By Route of Administration
- 8.4.3. By End-User
- 8.4.4. By Country
  - 8.4.4.1. Germany
  - 8.4.4.2. France
  - 8.4.4.3. UK
  - 8.4.4.4. Spain
  - 8.4.4.5. Italy
  - 8.4.4.6. Others
8.5. Middle East and Africa
- 8.5.1. By Indication
- 8.5.2. By Route of Administration
- 8.5.3. By End-User
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Israel
  - 8.5.4.4. Others
8.6. Asia Pacific
- 8.6.1. By Indication
- 8.6.2. By Route of Administration
- 8.6.3. By End-User
- 8.6.4. By Country
  - 8.6.4.1. Japan
  - 8.6.4.2. China
  - 8.6.4.3. India
  - 8.6.4.4. South Korea
  - 8.6.4.5. Indonesia
  - 8.6.4.6. Thailand
  - 8.6.4.7. Taiwan
  - 8.6.4.8. Others